When tirzepatide (Mounjaro/Zepbound) achieved average weight loss of 22.5% of body weight in the SURMOUNT-1 trial — exceeding semaglutide's 15% in the STEP-1 trial — it became the most clinically important question in metabolic medicine: why does tirzepatide outperform semaglutide, and does that mean everyone should switch?
The Mechanism Difference
Semaglutide is a GLP-1 receptor agonist — it mimics glucagon-like peptide 1, a hormone released from the gut after eating that stimulates insulin secretion, suppresses glucagon, slows gastric emptying, and signals satiety to the brain. Tirzepatide is a dual agonist — it activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor simultaneously.
GIP is a less-studied gut hormone that also stimulates insulin secretion and has important effects on fat metabolism. In adipose tissue, GIP promotes fat storage under normal conditions — which is why GIP receptor activation in the context of tirzepatide was initially surprising as a weight loss mechanism. The answer appears to lie in the specific pharmacology: tirzepatide's GIP agonism sensitizes GLP-1 receptor signaling rather than simply adding GIP effects to GLP-1 effects. The combination produces a synergistic effect on appetite suppression and metabolic signaling that exceeds either receptor alone.
Comparing the Trial Data
| Metric | Semaglutide (STEP-1) | Tirzepatide (SURMOUNT-1) |
|---|---|---|
| Average weight loss | 15.0% | 22.5% |
| % achieving ≥20% weight loss | ~30% | ~57% |
| HbA1c reduction (T2D) | 1.5–1.8% | 1.6–2.3% |
| Cardiovascular events (SELECT) | -20% (vs. placebo) | Ongoing trial (SURPASS-CVOT) |
Side Effect Comparison
Both drugs share the same class effect for GI side effects — nausea, vomiting, diarrhea, and constipation. Overall incidence appears similar between the two, though individual patient experiences vary. Some patients who could not tolerate semaglutide tolerate tirzepatide well, and vice versa. Both improve on careful dose titration and dietary modification.
Clinical Decision Making
For patients with type 2 diabetes or pre-diabetes with significant cardiovascular risk, semaglutide has the more established cardiovascular outcome data (SELECT trial). For patients whose primary goal is maximum weight loss, tirzepatide's superior efficacy makes it the first-line consideration. For patients who have not responded adequately to semaglutide, tirzepatide may produce meaningful additional benefit through its dual mechanism. Both require physician supervision, metabolic monitoring, and integration with lifestyle intervention.